PDXs recapitulate the complex genotypes and intratumoral heterogeneity of their tumors of origin and are not subject to the selective pressures imposed by in vitro cell culture since they are maintained exclusively in vivo [5] [6] [7] . These features have driven the rapid adoption and widespread use of PDXs in preclinical and co-clinical drug development, evaluation of biomarkers and imaging agents, and mechanistic investigation of acquired treatment resistance [8] [9] [10] . PDXs have also proven to be valuable models of tumor types or variants for which in vitro models are not readily available 11, 12 .
deletions (indels) by non-homologous end joining or to make precise genomic alterations through homology-directed repair (HDR) 15 . However, in vivo applications of CRISPRCas9 genome editing have been restricted to xenografts of established human cell lines and genetically engineered mouse models (GEMMs) due largely to the technical challenges imposed by the continuous in vivo passaging of PDXs and the need for alternative selection methods. Given the increasing role of PDXs in cancer research, a technological advance is needed to enable direct genome editing of PDXs using CRISPR-Cas9 to further our understanding of cancer biology and facilitate the development of new therapeutic strategies.
Tight temporal control of Cas9 activity in the cells that make up established tumors is essential to validate genes required for tumor maintenance and to credential suppressor mutations that may play a role in acquired drug resistance. Several inducible systems have been developed to regulate Cas9 activity at the posttranslational level, yet these systems invariably suffer from aberrant or reduced Cas9 activity [reviewed in 16 ] . Doxycycline (dox)-inducible expression of Cas9 provides a combination of maximum cutting efficiency in the "on" state while minimizing Cas9 activity in the "off" state through tight transcriptional regulation. However, current systems lack complete transcriptional control by dox and are not amenable to use in PDXs because they either rely on inefficient knock-in approaches [17] [18] [19] or employ vectors that exceed the lentiviral packaging limit and consequently result in low viral titers and predictably poor transduction efficiency 20, 21 . Importantly, all current modalities of inducible Cas9 expression lack a suitable selectable marker for use in PDXs.
To overcome these limitations and enable in vivo functional genomic studies in PDXs, we developed pSpCTRE, an all-in-one dox-inducible Cas9 lentiviral vector tailored for use in PDXs (Fig. 1a) . Leaky Cas9 expression is reduced by the placement of a TRE 3GS promoter in the reverse orientation relative to the viral LTRs 22 and through use of the rtTA-V10 variant 23 . Since lentiviral titer decreases as a function of proviral size 24 , several approaches were taken to minimize the size of pSpCTRE. A minimal EFS promoter is used to drive constitutive expression of rtTA-V10 as well as a truncated human CD4 selectable marker (hereafter CD4 T ), with the latter enabling rapid, positive selection of pSpCTRE-transduced cells without intervening in vitro culture. These optimizations collectively result in a final SpCTRE size of 9,023 bp between the LTRs.
The optimal composition of CD4 T was empirically determined through a deletion series of the extracellular Ig-like domains required for binding of commercial α-CD4
antibodies ( Supplementary Fig. 1a ). While several α-CD4 antibody epitopes reside within domain D 1 25 , we found that both domains D 1 Fig. 1d ).
In addition to mitigating leaky Cas9 expression, reverse orientation of the TRE
3GS
promoter places it proximal to the constitutive EFS promoter. This promoter topology is unidirectional in the absence of dox and potently induced bidirectionally in the presence of dox, markedly increasing CD4 T expressed from the EFS promoter ( Cas9-expressing SpCTRE PDXs can be generated from pSpCTRE lentivirus in as few as two in vivo passages (Fig. 1b) . In the first passage, dissociated tumors are subjected to an ex vivo spin transduction and immediately re-engrafted for expansion in vivo. Successfully transduced cells are enriched from the ensuing tumor with α-CD4
positive selection and either cryopreserved or passaged for subsequent use in functional genomic studies.
We initially examined SpCTRE editing efficiency through in vitro disruption of GFP in A549 cells with a single copy of GFP (A549 GFP ). In the absence of dox, A549 GFPSpCTRE cells transduced with sgGFP maintained GFP expression and had no detectable Cas9 protein by Western blot (Fig. 1c, d ). Conversely, after exposure to dox, A549 GFP -SpCTRE cells efficiently edited GFP, similar to A549 GFP cells constitutively expressing Cas9 from the lentiCas9-Blast vector (Fig. 1c, d ). We observed a dosedependent increase in Cas9 expression and CD4 T induction with concomitant loss of GFP expression with as little as 0.0625 µg/mL dox and a maximum loss of GFP expression at 0.25 µg/mL dox, defining an upper and lower bound for dox response ( Fig.   1e and Supplementary Fig. 2b ). To more sensitively screen for leaky expression of Cas9 and undesired genome editing, we cultured A549 GFP -SpCTRE cells transduced with sgGFP in the absence of dox. We observed no decrease in GFP-positive cells over >10 passages, yet these cells retained the capacity to efficiently disrupt GFP upon dox induction after 35 days of continuous culture (Fig. 1f) . These data indicate that pSpCTRE is a tightly regulated dox-inducible Cas9 vector, suggesting that this system is well suited for in vivo use in heterogeneous PDX tumors.
We next sought to generate a library of SpCTRE PDXs by transducing 20 PDXs representing multiple lung cancer subtypes with pSpCTRE lentivirus. We were able to detect and enrich CD4 T positive cells in six of these models ( Supplementary Fig. 3a ).
The median time to establish these SpCTRE PDXs following transduction was 154 days (with a range of 108 to 305 days) and one to three in vivo passages were required ( Supplementary Fig. 3b ). Importantly, these SpCTRE PDX tumors express Cas9 exclusively when the mice are administered dox ( Supplementary Fig. 3c ).
We first interrogated genetic dependencies of SpCTRE PDXs using a competition assay, which allows for measurement of gene disruption effects without prior selection for cells transduced with sgRNAs (Fig. 2a) . To deliver each sgRNA, we generated a fluorescent reporter lentiviral vector (sgTrack) that constitutively expresses either mCherry or GFP along with an sgRNA and can be produced at high titer. We We verified targeted editing of the RPA1 locus in isolated tumor cells and confirmed the presence of indels exclusively in sgRPA-transduced cells with CD4 T induced expression (Fig. 2c) To interrogate a broader spectrum of single nucleotide variants and compound genetic alterations found in human cancer, we generated a recombinant adenoassociated virus (rAAV) vector that delivers an sgRNA and a homology-directed repair template encoding multiple desired genetic alterations (Fig 3a) . To validate this approach in SpCTRE PDXs, we chose to explore mechanisms of acquired EGFR inhibitor resistance in lung adenocarcinomas. MSK-LX29 was derived from a patient with a homozygous EGFR L858R mutation who developed resistance to the 1 st generation EGFR inhibitor erlotinib through acquisition of a focal MET amplification. This PDX is resistant to single agent treatment with the 3 rd generation EGFR inhibitor osimertinib as well as the MET inhibitor crizotinib but is profoundly and durably sensitive to a combination therapy of the two drugs ( Supplementary Fig. 6a, b) .
We generated an rAAV vector that encodes both an sgRNA targeting a sequence proximal to the hydrophobic binding pocket of the EGFR kinase domain and a 1.5-kb repair template centered on this region. The repair template encodes base changes that silently destroy the sgEGFR PAM sequence to prevent Cas9 re-cutting after repair and introduces in cis 1) a T790M 1 st generation EGFR inhibitor gatekeeper mutation, 2) a C797S mutation that abolishes activity of 3 rd generation covalent EGFR inhibitors and 3) a silent landmark mutation to mark desired base changes that originate from the repair template (Fig. 3b) . Efficient generation of osimertinib resistance in EGFR-mutant PC9 cells using this template was confirmed in vitro ( Supplementary Fig. 7a-c) . While initially sensitive to a crizotinib-osimertinib combination therapy, within 2 weeks after the start of treatment MSK-LX29-SpCTRE infected with this rAAV developed resistance in all five tumors in this treatment group ( Fig. 3c and Supplementary Fig. 6c ). All five resistant tumors demonstrated efficient editing and selection for the templated C797S mutation (Fig. 3d, e) . We conclude that an acquired resistance mutation in EGFR alone is sufficient to restore resistance to crizotinib-osimertinib combination therapy in EGFR mutant lung adenocarcinomas that acquire bypass resistance through MET amplification. More generally, these data confirm that pSpCTRE can be used to introduce template-directed site-specific mutations in vivo. 
METHODS

Patient-derived xenografts (PDXs)
All animal experiments were approved by the Memorial Sloan Kettering Cancer Center (MSKCC) Animal Care and Use Committee. Primary tumors and whole blood samples collected for generation of PDX models were obtained with informed consent from patients under protocols approved by the MSKCC and Johns Hopkins institutional review boards. Subcutaneous flank tumors were generated as described previously 9 .
Cloning and plasmids
The plasmids generated in this study are available on Addgene as indicated. A list of all primers used in this study is available in Supplementary Table S1 . were cloned into these vectors as previously described 28 .
pAAV-GFP-sgHDR: pAAV-GFP was a gift from John T Gray (Addgene plasmid # 32395) 29 . A synthetic DNA fragment comprising an SV40 polyA terminator, partial multiple cloning site (BglII, HindIII), the human U6 promoter, EGFR sgRNA, a 1.5 kb EGFR homology directed repair template containing the T790M mutation and destroying the sgEGFR PAM sequence, and a second partial multiple cloning site (ClaI, XhoI, XbaI)
was cloned into the NotI and XbaI restriction enzyme sites of pAAV-GFP, replacing the original beta-globin polyA fragment. EGFR C797S coding and silent repair landmark mutations were inserted via site directed mutagenesis using primer pair P1 to generate the rAAV vector. CD4ΔD [2] [3] [4] ;ΔIC linked to rtTA-V10 by a T2A sequence was generated by gene synthesis (IDT), Gateway adapted by PCR using primer pair P2, and cloned into pDONR221. CD4 domain D 2 was then added to this construct to generate CD4ΔD [3] [4] ;ΔIC (CD4 T ) by performing an outward PCR with primer pair P3, extracting domain D 2 from pDONR221/CD4 using primer pair P4 and performing a Gibson assembly (NEB) with the PCR products. All CD4 constructs were then cloned into pLenti CMV Puro (w118-1).
sgRNAs were cloned into lentiGuide-Puro as previously described 28 . 
sgRNA sequences
Target sequences for sgRNAs used in this study are available in Supplementary Table   S2 .
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Cell culture and lentivirus production A549, PC9, and HEK239T cells were purchased from ATCC. A549 and PC9 cells were 
Antibodies
A list of antibodies used in this study is available in Supplementary Table S3 .
Protein extraction, Western blotting and LiCor protein quantification
Whole cell lysates were prepared from frozen cell pellets or flash frozen tumor samples using RIPA lysis buffer with 1x HALT protease inhibitor cocktail (Thermo). Cell pellets were resuspended in 5 volumes of cold lysis buffer and incubated on ice for 10 minutes, followed by sonication for 10 seconds with a 200V microtip sonicator set to 40% amplitude (QSonica, CL 18). Lysates were clarified by centrifugation at 20,000 x g for 10 minutes at 4C. Protein extraction from flash frozen tumor samples was performed as previously described 9 . Protein was quantified using a BCA protein assay kit (Pierce) and samples were denatured at 70C for 10 minutes in NuPAGE LDS sample buffer with NuPAGE sample reducing agent and then resolved on a 4-12% Bis-Tris gradient gel (Invitrogen). For chemiluminescent detection, gels were wet-transferred to 0.45 µm Immobilon-P PVDF membrane (Millipore) and incubated overnight at 4C with primary antibody diluted in TBS (Fisher) supplemented with 0.1% Tween20 (Fisher) and either 5% BSA (Cell Signaling) or 5% non-fat dry milk (Oxoid). Blots were then incubated at room temperature for 1 hour with the relevant secondary antibody diluted in TBS supplemented with 0.1% Tween20 and 5% non-fat dry milk and then detected using ECL Western Blotting Substrate (Pierce). Protein transfer, detection, and quantification using
LiCor was performed as previously described 9 .
Tracing of Indels by Decomposition (TIDE) analysis
Genomic DNA was extracted from cell pellets using the DNeasy Blood & Tissue kit (Qiagen). An approximately 800-bp region centered on the sgRNA cut site was PCR amplified from 50 ng of genomic DNA using primer pair P5 (sgGFP) or P6 (sgRPA1-1)
(Supplementary Table S1 ). Completed PCR reactions were treated with exonuclease I (NEB) according to the manufacturer's protocol and then purified with the QIAquick PCR purification kit (Qiagen). 20 ng of purified PCR product was Sanger sequenced using an M13-forward primer and chromatograms were analyzed as previously described 34 .
Flow cytometry analysis for in vitro experiments
A549-SpCTRE or A549 GFP -SpCTRE cells for flow cytometry analysis were collected using TrypLE Express (Thermo) according to the manufacturer's protocol to preserve was transduced with pLenti CMV Puro/CD4 lentivirus and selected with puromycin for 3
days. This cell lines was mixed with A549 GFP -SpCTRE and flow cytometry analysis was performed as described above using anti-human CD4 antibodies RPA-T4 (APC) and OKT4 (PE).
Magnetic cell separation (MACS)
A549-SpCTRE cells were spiked into an A549 GFP cell suspension at an abundance of 5-20%. This mixture was incubated with CD4 microbeads (Miltenyi) and subjected to magnetic separation with LS columns (Miltenyi) according to the manufacturer's protocol. Eluted cells were cultured for 3 days to allow for dissociation of magnetic beads and then collected for flow cytometry analysis of CD4 T purity, as described above.
Results represent three independent biological replicates.
Transduction and enrichment of SpCTRE PDXs
Established PDX tumors were resected and dissociated to a single cell suspension using SNP profiles of SpCTRE PDXs were compared to pre-sorted samples using qPCR genotyping of 8 informative SNPs to confirm identity.
In vivo competition assays in SpCTRE PDXs
Established SpCTRE PDX tumors were dissociated to a single cell suspension, red blood cells were lysed, and mouse stroma was removed as described above. Cells were then independently transduced ex vivo with sgTrack lentivirus at a relative MOI of 1 as described above. Each sgTrack transduced SpCTRE PDX was engrafted in a 50%
Matrigel mixture into a single flank of a 6-8 week old NSG or Nude mouse. Resulting tumors were dissociated to a single cell suspension, red blood cells were lysed, and mouse stroma was removed as described above. Cells containing control and test sgRNAs were mixed with an equal ratio of GFP and mCherry positive cells and engrafted in a 50% Matrigel mixture into a single flank of 6-8 week old NSG or Nude mice. Once tumors reached ~100 mm 3 , mice were randomized to control or dox-treated groups, with dox-treated mice receiving 625 mg/kg doxycycline chow (Envigo). Tumors were collected once they reached 1000 mm 3 , dissociated to a single cell suspension, and prepared for flow cytometry analysis or sorting as described above. Indel analysis of sorted cells was performed as described above and fitness scores and log ratios were calculated as described in Supplementary Fig. 4b . The Wilcoxon rank sum statistic was used to test if the fitness scores in the dox-treated group were smaller than the fitness scores in the control group.
Recombinant AAV production and validation
Recombinant AAV2/6 pseudotyped virus was produced by the Boston Children's Hospital Viral Core. PC9 cells transduced with lentiCas9-Blast and selected with blasticidin for 7 days were subsequently transduced with rAAV at an MOI of 2.3. Control and rAAV transduced PC9-lentiCas9-Blast cells were treated with 1 µM osimertinib (Selleck Chemicals) or DMSO (Corning) until they reached confluency, at which time cell pellets were collected for genomic analysis, described below. Osimertinib resistance was confirmed in cells previously transduced with rAAV and selected with osimertinib by seeding 3000 viable cells per well in 100 µL/well media containing a dilution series of osimertinib. Viability was assayed 72 h after plating using CellTiter-Glo (Promega).
In vivo homology-directed repair in MSK-LX29
Crizotinib (LC Laboratories), osimertinib (LC Laboratories), or the combination were formulated in 0.5% hydroxypropyl methylcellulose (HPMC) and given by oral gavage at 25 mg/kg daily for 5 days per week. An MSK-LX29-SpCTRE tumor from a mouse fed with dox chow for 4 weeks prior to dissociation was incubated with the rAAV at an MOI of 1.6 million genomic copies/cell for 1 hour at 37C. Cells were washed twice with PBS and then engrafted in a 50% Matrigel mixture in the flank of 6-8 week old NSG mice. All mice were administered dox chow at the time of engraftment and treatment groups were randomized once tumors reached 100 mm 3 . Tumors were collected once they reached 1000-1500 mm 3 and genomic analysis was performed as described below.
Genomic analysis of EGFR homology-directed repair
Genomic DNA was purified from dissociated tumors or cell pellets using the Gentra Puregene Cell kit (Qiagen). A 1,122 bp amplicon, which spans outside the rAAV homology arms to ensure amplification occurs from genomic DNA, was PCR amplified from 200 µg genomic DNA using primer pair P7. The PCR product was then digested with exonuclease I to remove excess primers, column purified using the QIAquick PCR purification kit (Qiagen), and 100 µg was used as the template for a second PCR with primer pair P8 to amplify a 273 bp region centered on the repair site. The second round PCR product was column purified and paired-end Next-Gen sequencing (NGS) was performed by the CCIB DNA Core Facility at Massachusetts General Hospital (Cambridge, MA). NGS sequencing was analyzed using the R statistical computing environment to determine the proportion of reads that underwent rAAV-mediated homology-directed repair. 
